Florham Park-based Phathom Pharmaceuticals on Tuesday said that, effective April 5, Molly Henderson will be its new chief financial and business officer.
Most recently serving as CFO of UroGen Pharma, Henderson brings over two decades of global finance expertise and has extensive experience in financial planning and analysis, investor relations and capital raising.
“Molly brings to Phathom deep financial acumen and significant industry experience across midsize and large-scale commercial organizations, and we are excited to have her join our executive leadership team,” said Terrie Curran, CEO and president of Phathom. “Phathom’s corporate finance, strategy and business development capabilities will be further enhanced through Molly’s leadership as we accelerate our evolution into a commercial-stage company.”
Henderson has extensive experience in the pharmaceutical industry and currently serves as a member of the board of directors and chair of the audit committee of Calliditas Therapeutics A.B. She was previously the executive vice president and CFO of Advaxis Inc., CFO of Iovance Biotherapeutics Inc. (formerly Lion Biotechnologies Inc.) and, prior to then, the chief business and financial officer and senior vice president of VirtualScopics Inc.
